Serological association between Chlamydia pneumoniae infection and age-related macular degeneration

Archives of Ophthalmology

Volumn 121, Issue 4, 2003, Pages 478-482

  Kalayoglu, Murat V ^a   Galvan, Carlos ^b   Mahdi, Olaimatu S ^c   Byrne, Gerald I ^c   Mansour, Sam ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; CHAPERONIN; HEAT SHOCK PROTEIN 60; PROTEIN ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; ATHEROSCLEROSIS; BLINDNESS; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ESCHERICHIA COLI; FEMALE; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SEROLOGY; UNITED STATES;

AGED; ANTIBODIES, BACTERIAL; CASE-CONTROL STUDIES; CHAPERONIN 10; CHAPERONIN 60; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE INFECTIONS, BACTERIAL; FEMALE; GROEL PROTEIN; GROES PROTEIN; HUMANS; MACULAR DEGENERATION; MALE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

EID: 0037386730     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.4.478     Document Type: Article

References (38)

1. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. 2000;342:483-492.
2. Hawkins BS, Bird A, Klein R, West SK. Epidemiology of age-related macular degeneration. Mol Vis. 1999;5:26.
3. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2000;130;658-663.
4. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105:1135-1143
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115-126.
6. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
7. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1998;39:2194-2200.
8. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001;158:1161-1172.
9. Anderson DH, Ozaki S, Nealon M, et al. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol. 2001;131:767-781.
10. Dithmar S, Curcio CA, Le NA, Brown S, Grossniklaus HE. Ultrastructural changes in Bruch's membrane of apolipoprotein E-deficient mice. Invest Ophthalmol Vis Sci. 2000;41:2035-2042.
11. Kliffen M, Lutgens E, Daemen MJ, de Muinck ED, Mooy CM, de Jong PT. The APO(*)E3-Leiden mouse as an animal model for basal laminar deposit. Br J Ophthalmol. 2000;84:1415-1419
12. Spaide RF, Ho-Spaide WC, Browne RW, Armstrong D. Characterization of peroxidized lipids in Bruch's membrane. Retina. 1999;19:141-147.
13. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and agerelated macular degeneration. Mol Vis. 1999;5:32.
14. Kalayoglu MV, Byrne GI. Chlamydia. In: Dworkin M, ed. Prokaryotes. Vol 3. New York, NY: Springer-Verlag; 2001:e1-e16.
15. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288:2724-2731.
16. Saikku P. Epidemiology of Chlamydia pneumoniae in atherosclerosis. Am Heart J. 1999;138:S500-S503.
17. Kuo C, Campbell LA. Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis. 2000;181(suppl 3):S432-S436.
18. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med. 1996;125:979-982.
19. Kalayoglu MV, Byrne GI. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis. 1998;177:725-729.
20. Kalayoglu MV, Byrne GI. A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopoysaccharide. Infect Immun. 1998; 66:5067-5072.
21. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, Byrne GI. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis. 1999;180:780-790.
22. Kalayoglu MV, Miranpuri GS, Golenbock DT, Byrne GI. Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumomae. Microbes Infect. 1999;1:409-418.
23. Kaukoranta-Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog. 1996; 21:215-221.
24. Kaukoranta-Tolvanen SS, Ronni T, Leinonen M, Saikku P, Laitinen K. Expression of adhesion molecules on endothelial cells stimulated by Chlamydia pneumoniae. Microb Pathog. 1996;21:407-411.
25. Kalayoglu MV, Perkins BN, Byrne GI. Chlamydia pneumoniae-infected monocytes exhibit increased adherence to human aortic endothelial cells. Microbes Infect. 2001;3:963-969.
26. Campbell LA, Blessing E, Rosenfeld M, Lin T, Kuo C. Mouse models of C pneumoniae infection and atherosclerosis. J Infect Dis. 2000;181(suppl 3):S508-S513.
27. Muhlestein JB. Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. J Infect Dis. 2000;181(suppl 3):S505-S507.
28. Rosen H, Muhlestein JB, Bartlett J, et al. Collaborative multidisciplinary workshop report: clinical antimicrobial trials for primary and secondary prevention of atherosclerotic cardiovascular disease. J Infect Dis. 2000;181(suppl 3):S582-S584.
29. Yuan Y, Lyng K, Zhang YX, Rockey DD, Morrison RP. Monoclonal antibodies define genus-specific, species-specific, and cross-reactive epitopes of the chlamydial 60-kilodalton heat shock protein (hsp60): specific immunodetection and purification of chlamydial hsp60. Infect Immun. 1992;60:2288-2296.
30. La Verda D, Byrne GI. Use of monoclonal antibodies to facilitate identification, cloning and purification of Chlamydia trachomatis hsp10. J Clin Microbiol. 1997; 35:1209-1215.
31. Caldwell HD, Kromhout J, Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun. 1981;31:1161-1176.
32. LaVerda D, Albanese LN, Ruther PE, et al. Seroreactivity to Chlamydia trachomatis Hsp10 correlates with severity of human genital tract disease. Infect Immun. 2000;68:303-309.
33. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation. 1999;99:1560-1566.
34. Gehrs KM, Heriot WJ, de Juan E Jr. Transmission electron microscopic study of a subretinal choroidal neovascular membrane due to age-related macular degeneration. Arch Ophthalmol. 1992;110:833-837
35. Airenne S, Surcel HM, Alakarppa H, et al. Chlamydia pneumoniae infection in human monocytes. Infect Immun. 1999;67:1445-1449.
36. Kaul R, Wenman WM. Chlamydia pneumoniae facilitates monocyte adhesion to endothelial and smooth muscle cells. Microb Pathog. 2001;30:149-155.
37. Maass M, Gieffers J, Solbach W. Atherogenetically relevant cells support continuous growth of Chlamydia pneumoniae. Herz. 2000;25:68-72.
38. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation. 1998;98:300-307.